Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Patients with spontaneous decline of HBV DNA were non-randomly assigned to accept
peginterferon alfa-2a or entecavir therapy, or didn't accept any antiviral regiment.